Dr. Sarina Elmariah explains the importance of neuroimmune crosstalk in the development of prurigo nodularis.
Dr. Sarina Elmariah explores the complex systemic burden of PN, from diverse clinical presentations and delayed diagnosis to the profound impact of itch, sleep disruption, comorbidities, and reduced quality of life.
Join Drs. Martin Metz, Moshe Ben-Shoshan, and Michelle Tarbox as they share expert insights on the burden of pediatric CSU, as well as key considerations for disease diagnosis and treatment escalation in pediatric and adult patients.
Drs Martin Metz, Moshe Ben-Shoshan, and Michelle Tarbox shared expert perspectives on chronic spontaneous urticaria (CSU) during an engaging ADVENT symposium at EADV 2026 in Vienna, Austria. The symposium explored key considerations across the CSU patient journey, from diagnosis to disease control. Key topics included the multifaceted burden of CSU on patients, caregivers, and families, practical approaches to diagnosis and assessment of disease control, and considerations for treatment escalation and advanced therapy selection in adult and pediatric patients with CSU.
Dive into the complex pathophysiology of chronic spontaneous urticaria (CSU), where mast cell degranulation drives the hallmark signs and symptoms. This interactive infographic elucidates how key type 2 cytokines, specifically IL-4 and IL-13, contribute to mast cell activation, immune cell trafficking into the skin, and neuronal sensitization in CSU, which ultimately leads to the release of mediators like histamine that cause wheals, angioedema, and itch.
Experts from different specialties use a case-based discussion to understand type 2 inflammatory diseases from a nurse practitioner perspective.

Associate Professor and Dermatology Director at the UCSF Centre for Itch and Neurosensory Disorders at the University of California in San Francisco, California, US
Dr. Pedro Bastos shares how real-world evidence for approved biologics is essential to inform the treatment of PN across diverse comorbid patient populations, including insights into rapid itch relief, progressive skin clearance, long-term outcomes, and safety.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Brian Kim describes the dynamic neuroimmune interactions in chronic pruritic skin diseases, emphasizing how type 2 cytokines and sensory nerves actively influence both itch perception and tissue inflammation.

In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Stephan Weidinger discusses how type 2 inflammation contributes to epidermal barrier dysfunction, perivascular infiltration and plasma protein leakage, and chronic itch in AD.

This infographic highlights how uncontrolled moderate‑to‑severe atopic dermatitis (AD) can lead to Cumulative Life Course Impairment (CLCI) by contributing to ongoing physical, psychological, and social burdens such as itch and sleep loss, impaired bone growth and mental health challenges. It emphasizes the importance of early and effective disease control to help reduce long‑term impact on patients.